Eli Lilly鈥檚 recently-announced investment into the UK鈥檚 life sciences sector 鈥渕arks a pivotal moment for the industry鈥�, according to GlobalData鈥檚 senior analyst in business fundamentals Ophelia Chan.
Considering the 拢279mn ($365.5mn) investment, announced at International Investment Summit on 14 October, Chan said: 鈥淟illy鈥檚 investment, coupled with the UK government鈥檚 support for life sciences and healthcare, marks a pivotal moment for the industry.
鈥淏y fostering innovation, tackling health challenges like obesity, and driving economic growth, this collaboration highlights the impact of public-private partnerships on national health and economic advancement.鈥�
The initiative will look to advance treatments for obesity, which currently costs the NHS over 拢11bn ($14.4bn) annually. Eli Lilly is already a major player in the obesity treatment space with its GLP-1R drug Zepbound; there was a shortage of the drug until last week, when on 19 December.
Lilly鈥檚 investment in the UK鈥檚 life sciences sector will include a Lilly Gateway Labs facility, which will support startups in the UK鈥檚 life science space. The first in Europe and described as an 鈥榠nnovation accelerator鈥�, it will include lab space, mentorship, and financial support for startups which are looking to develop transformative medicines.
Chan commented that, 鈥淏y combining life sciences expertise with healthcare innovation, the effort seeks to deliver lasting health benefits for those affected by obesity.鈥�
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataHer optimism echoed that of science and technology secretary Peter Kyle, who in October. He highlighted the collaboration鈥檚 role in driving the economy and contributing to 鈥渃reating the jobs, opportunity, and growth we need to invest further in health and to push up living standards.鈥�
The investment spells good news for the UK government then, which has already shared its plans to promote a healthy life sciences sector. In the budget announced on 30 October, chancellor Rachel Reeves shared plans to provide 拢520m ($670m) for a new Life Sciences Innovative Manufacturing Fund and committed to maintaining current rates of R&D tax relief.
The budget also included a 拢25.7bn ($33.6bn) funding boost for the NHS 鈥� the largest since 2010 (excluding Covid-19 periods). Key measures for improvements in the NHS included plans for 40,000 extra weekly elective appointments and 18-week treatment targets. They were accompanied by plans to provide 拢1.5bn ($1.9bn) for surgical hubs enabling 30,000 additional procedures annually, as well as over 1.25 million advanced diagnostic tests.
